This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Jazz's (JAZZ) Leukemia Drug Vyxeos Gets Approval in Europe
by Zacks Equity Research
Jazz Pharmaceuticals' (JAZZ) Vyxeos receives marketing approval from the European Commission for treating acute myeloid leukemia.
Pacira (PCRX) Rides High on Robust Exparel Performance
by Zacks Equity Research
Pacira (PCRX) focuses on improving sales of its flagship product Exparel. The drug's label expansion programs also look encouraging.
Pacira Pharmaceuticals (PCRX): Moving Average Crossover Alert
by Zacks Equity Research
Pacira Pharmaceuticals, Inc. (PCRX) is looking like an interesting pick from a technical perspective
Pacira (PCRX) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Pacira (PCRX) encourages investors with better-than-expected earnings and revenues in Q2.
Pacira (PCRX) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Pacira (PCRX) delivered earnings and revenue surprises of 166.67% and 5.65%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
What's in Store for Catalyst (CPRX) This Earnings Season?
by Zacks Equity Research
Investors' focus will be on Catalyst's (CPRX) pipeline candidates, Firdapse and CPP-115, and regulatory updates, during the second-quarter earnings call.
What's in Store for Intrexon (XON) This Earnings Season?
by Zacks Equity Research
Investors are likely to remain focused on Intrexon's (XON) performance along with other developmental updates during second-quarter 2018 earnings call.
What's in Store for Epizyme (EPZM) This Earnings Season?
by Zacks Equity Research
Investors are likely to remain focused on Epizyme's (EPZM) lead candidate, tazemetostat, in the second quarter earnings call.
Will ACADIA (ACAD) Disappoint Investors in Q2 Earnings?
by Zacks Equity Research
On ACADIA's (ACAD) second-quarter 2018 conference call, investor focus will be on the sales figures of its only marketed drug Nuplazid as well as its pipeline progress.
AVEO Pharmaceuticals (AVEO) Q2 Earnings: What's in Store?
by Zacks Equity Research
On AVEO Pharmaceuticals' (AVEO) second-quarter 2018 conference call, investors' focus will remain on the company's progress with its drug Fotivda for the first-line treatment of RCC.
Zoetis (ZTS) Gears Up for Q2 Earnings: What's in Store?
by Zacks Equity Research
We expect Zoetis (ZTS) to throw more light on its Abaxis acquisition plans and other pipeline updates during second-quarter 2018 earnings call.
Aerie (AERI) to Report Q2 Earnings: What's in the Offing?
by Zacks Equity Research
Investors will focus on Rhopressa's initial uptake, and other pipeline and regulatory updates, when Aerie (AERI) reports Q2 results.
Regeneron (REGN) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Investors' focus will be on the company's performance, particularly on Eylea and Dupixient's uptake during Regeneron's (REGN) second-quarter earnings call.
Will Agenus (AGEN) Disappoint Investors This Earnings Season?
by Zacks Equity Research
In the second quarter of 2018, Agenus (AGEN) should focus on its pipeline candidates and provide updates on them as many of its pipeline candidates are under evaluation for various indications.
What's in Store for Intercept (ICPT) This Earnings Season?
by Zacks Equity Research
Investors will primarily focus on Ocaliva's performance along with other pipeline developments, when Intercept (ICPT) reports its Q2 results on Aug 2.
What's in Store for Immune Design (IMDZ) in Q2 Earnings?
by Zacks Equity Research
We expect Immune Design (IMDZ) to focus on the progress of its pipeline candidates in the second quarter earnings call.
Is a Beat in Store for Endocyte (ECYT) This Earnings Season?
by Zacks Equity Research
The investor's focus is expected to remain on updates from pipeline candidates 177Lu-PSMA-617, CAR-T cell program during the Q2 earnings call.
Pacira Focused on Exparel Development Amid Competition
by Zacks Equity Research
Pacira (PCRX) focuses on the label expansion of its flagship product, Exparel.
Pacira (PCRX) Issues Strong Preliminary Exparel Sales for Q2
by Zacks Equity Research
Pacira (PCRX) announces robust preliminary results for Exparel sales in second quarter on the back of increasing adoption for pain management in surgical procedures.
Pacira Pharmaceuticals (PCRX) Up 3.5% Since Earnings Report: Can It Continue?
by Zacks Equity Research
Pacira Pharmaceuticals (PCRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
FDA Okays Label Expansion of Pacira's Exparel's, Stock Up
by Zacks Equity Research
Shares of Pacira (PCRX) jump by about 12.9% after its drug Exparel gets approval by the FDA for an expanded indication.
Company News For Apr 9, 2018
by Zacks Equity Research
Companies in the news are: PSMT,CPB,BWEN,PCRX
Pacira Pharmaceuticals (PCRX) Soars: Stock Adds 12.9% in Session
by Zacks Equity Research
Pacira Pharmaceuticals (PCRX) was a big mover last session, as the company saw its shares rise more than 12% on Friday amid huge volumes.
Pacira Pharmaceuticals (PCRX) Down 4.7% Since Earnings Report: Can It Rebound?
by Zacks Equity Research
Pacira Pharmaceuticals (PCRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Heron's Pain Candidate Meets Endpoint in Pivotal Studies
by Zacks Equity Research
Heron Therapeutics' (HRTX) pipeline candidate, HTX-011, meets primary endpoint in two pivotal phase III studies in bunionectomy and hernia repair.